Literature DB >> 16986039

Advanced prostate cancer: an update.

A Ziada, E D Crawford, F H Schröeder, M E Gleave, P D Miller, M B Garnick.   

Abstract

A number of therapeutic options are available or on the horizon for patients for whom initial treatment of localized prostate cancer has failed. Currently under study are time of therapy, maximum androgen blockade, and palliative and adjunctive therapies.

Entities:  

Year:  2000        PMID： 16986039      PMCID： PMC1557462     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  18 in total

Review 1.  Management of osteoporosis.

Authors:  P D Miller
Journal:  Adv Intern Med       Date:  1999

2.  Proposed substages for metastatic prostate cancer.

Authors:  E D Crawford; B A Blumenstein
Journal:  Urology       Date:  1997-12       Impact factor: 2.649

3.  Hormonal Therapy in the Management of Prostate Cancer: An Historical Overview.

Authors: 
Journal:  Mol Urol       Date:  1999

4.  The effects of external beam radiotherapy on endocrine function in patients with carcinoma of the prostate.

Authors:  P W Grigsby; C A Perez
Journal:  J Urol       Date:  1986-04       Impact factor: 7.450

5.  Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group.

Authors: 
Journal:  Br J Urol       Date:  1997-02

6.  Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies.

Authors:  D P Byar; D K Corle
Journal:  NCI Monogr       Date:  1988

7.  Combined finasteride and flutamide therapy in men with advanced prostate cancer.

Authors:  D K Ornstein; G S Rao; B Johnson; E T Charlton; G L Andriole
Journal:  Urology       Date:  1996-12       Impact factor: 2.649

8.  Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer.

Authors:  J D Petronis; F Regan; K Lin
Journal:  Clin Nucl Med       Date:  1998-10       Impact factor: 7.794

9.  The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer.

Authors:  J T Isaacs
Journal:  Prostate       Date:  1984       Impact factor: 4.104

10.  Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma.

Authors:  P Karling; M Hammar; E Varenhorst
Journal:  J Urol       Date:  1994-10       Impact factor: 7.450
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.